Advisory Committee on Immunization Practices (ACIP), 60474 [2014-23856]
Download as PDF
<![CDATA[
60474
Federal Register / Vol. 79, No. 194 / Tuesday, October 7, 2014 / Notices
asabaliauskas on DSK5VPTVN1PROD with NOTICES
2001, renewed at appropriate intervals, and
will expire on August 3, 2015.
Purpose: The Advisory Board is charged
with (a) providing advice to the Secretary,
HHS, on the development of guidelines
under Executive Order 13179; (b) providing
advice to the Secretary, HHS, on the
scientific validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at any
Department of Energy facility who were
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is reasonable likelihood
that such radiation doses may have
endangered the health of members of this
class. The Subcommittee for Dose
Reconstruction Reviews was established to
aid the Advisory Board in carrying out its
duty to advise the Secretary, HHS, on dose
reconstruction.
Matters for Discussion: The agenda for the
Subcommittee meeting includes the
following dose reconstruction program
quality management and assurance activities:
Discussion of current findings from NIOSH
and Advisory Board dose reconstruction
blind reviews; discussion of dose
reconstruction cases under review (cases
involving Hanford, Mound Plant, Y–12, Oak
Ridge National Laboratory, Lawrence
Livermore National Laboratory, Pacific
Proving Grounds, Hooker Electrochemical,
Simonds Saw and Steel, Bethlehem Steel,
Weldon Spring, W.R. Grace, Westinghouse,
International Minerals and Chemical (IMC)
Corporation, Koppers Company, Bridgeport
Brass, Uranium Mill in Monticello, General
Steel Industries, and DuPont Deepwater
Works); and preparation of the Advisory
Board’s next report to the Secretary, HHS,
summarizing the results of completed dose
reconstruction reviews.
The agenda is subject to change as
priorities dictate.
Contact Person for More Information:
Theodore Katz, Designated Federal
Officer, NIOSH, CDC, 1600 Clifton Road
NE., Mailstop E–20, Atlanta GA 30333,
Telephone (513)533–6800, Toll Free
1(800)CDC–INFO, Email ocas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–23857 Filed 10–6–14; 8:45 am]
BILLING CODE 4163–19–P
VerDate Sep<11>2014
17:15 Oct 06, 2014
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
In accordance with section 10(a) (2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following meeting of the
aforementioned committee.
[FR Doc. 2014–23856 Filed 10–6–14; 8:45 am]
Times and Dates:
8:00 a.m.–5:45 p.m., EDT, October 29, 2014
8:00 a.m.–1:15 p.m., EDT, October 30, 2014
Place: Centers for Disease Control and
Prevention, Tom Harkin Global
Communications Center, 1600 Clifton Road
NE., Building 19, Kent ‘‘Oz’’ Nelson
Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate use of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines. Further, under
provisions of the Affordable Care Act, at
section 2713 of the Public Health Service
Act, immunization recommendations of the
ACIP that have been adopted by the Director
of the Centers for Disease Control and
Prevention must be covered by applicable
health plans.
Matters for Discussion: The agenda will
include discussions on: General
recommendations; human papillomavirus
vaccines; influenza; novel influenza
vaccines, tetanus, diphtheria, and acellular
pertussis vaccine (Tdap); meningococcal
vaccines; child/adolescent immunization
schedule; adult immunization schedule;
immunization safety; hepatitis vaccines;
typhoid vaccines; and vaccine supply.
Recommendation votes are scheduled for
general recommendations, child/adolescent
immunization schedule, adult immunization
schedule and typhoid vaccines. Time will be
available for public comment.
Agenda items are subject to change as
priorities dictate. Contact Person for More
Information: Stephanie Thomas, National
Center for Immunization and Respiratory
Diseases, CDC, 1600 Clifton Road NE., MS–
A27, Atlanta, Georgia 30333, telephone 404/
639–8836; Email ACIP@CDC.GOV
Meeting is Webcast live via the World
Wide Web; for instructions and more
information on ACIP please visit the ACIP
Web site: https://www.cdc.gov/vaccines/acip/
index.html.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
Food and Drug Administration
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2014–N–0386]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Orphan Drugs;
Common European Medicines Agency/
Food and Drug Administration
Application Form for Orphan Medicinal
Product Designation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(PRA).
SUMMARY:
Fax written comments on the
collection of information by November
6, 2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0167. Also
include the FDA docket number found
in brackets in the heading of this
document.
DATES:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\07OCN1.SGM
07OCN1
]]>Agencies
[Federal Register Volume 79, Number 194 (Tuesday, October 7, 2014)]
[Notices]
[Page 60474]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-23856]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices (ACIP)
In accordance with section 10(a) (2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announce the following meeting of the aforementioned
committee.
Times and Dates:
8:00 a.m.-5:45 p.m., EDT, October 29, 2014
8:00 a.m.-1:15 p.m., EDT, October 30, 2014
Place: Centers for Disease Control and Prevention, Tom Harkin
Global Communications Center, 1600 Clifton Road NE., Building 19,
Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director,
CDC, on the appropriate use of immunizing agents. In addition, under
42 U.S.C. 1396s, the committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children (VFC) program, along with schedules regarding the
appropriate periodicity, dosage, and contraindications applicable to
the vaccines. Further, under provisions of the Affordable Care Act,
at section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been adopted by the Director
of the Centers for Disease Control and Prevention must be covered by
applicable health plans.
Matters for Discussion: The agenda will include discussions on:
General recommendations; human papillomavirus vaccines; influenza;
novel influenza vaccines, tetanus, diphtheria, and acellular
pertussis vaccine (Tdap); meningococcal vaccines; child/adolescent
immunization schedule; adult immunization schedule; immunization
safety; hepatitis vaccines; typhoid vaccines; and vaccine supply.
Recommendation votes are scheduled for general recommendations,
child/adolescent immunization schedule, adult immunization schedule
and typhoid vaccines. Time will be available for public comment.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Stephanie Thomas, National
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton
Road NE., MS-A27, Atlanta, Georgia 30333, telephone 404/639-8836;
Email ACIP@CDC.GOV
Meeting is Webcast live via the World Wide Web; for instructions
and more information on ACIP please visit the ACIP Web site: https://www.cdc.gov/vaccines/acip/.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2014-23856 Filed 10-6-14; 8:45 am]
BILLING CODE 4160-18-P
